[HTML][HTML] The efficacy and toxicity of afatinib in advanced EGFR-positive non-small-cell lung cancer patients after failure of first-generation tyrosine kinase inhibitors: a …
Y Zhang, S Miao, F Wang, W Fang, G Chen… - Journal of Thoracic …, 2017 - ncbi.nlm.nih.gov
Background The first generation epidermal growth factor receptor-tyrosine kinase inhibitors
(EGFR-TKIs), gefitinib and erlotinib, have become the standard first-line treatment for non …
(EGFR-TKIs), gefitinib and erlotinib, have become the standard first-line treatment for non …
Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine …
VHF Lee, DKC Leung, TS Choy, KO Lam, PM Lam… - BMC cancer, 2016 - Springer
Background Afaitnib has shown anti-tumor activity against metastatic EGFR-mutated NSCLC
after prior failure to first generation EGFR-TKI and chemotherapy. We prospectively …
after prior failure to first generation EGFR-TKI and chemotherapy. We prospectively …
A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402)
T Yokoyama, H Yoshioka, D Fujimoto, Y Demura… - Lung Cancer, 2019 - Elsevier
Objectives Afatinib is an effective treatment in patients who have epidermal growth factor
receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC), but its toxicities …
receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC), but its toxicities …
A randomized phase II study of afatinib alone or combined with bevacizumab for treating chemo-naïve patients with non-small cell lung cancer harboring EGFR …
T Ninomiya, N Ishikawa, T Kozuki, S Kuyama, K Inoue… - Lung Cancer, 2023 - Elsevier
Background Adding bevacizumab to first-generation epidermal growth factor receptor
(EGFR)-tyrosine kinase inhibitors (TKIs) prolonged the progression-free survival (PFS), but …
(EGFR)-tyrosine kinase inhibitors (TKIs) prolonged the progression-free survival (PFS), but …
[HTML][HTML] Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX …
Background Afatinib 40 mg/day is approved for first-line treatment of EGFR mutation-positive
non-small-cell lung cancer (NSCLC). In the case of drug-related grade≥ 3 or selected …
non-small-cell lung cancer (NSCLC). In the case of drug-related grade≥ 3 or selected …
Clinical activity of afatinib in patients with non–small-cell lung cancer harboring uncommon EGFR mutations: a Spanish retrospective multicenter study
Introduction Uncommon epidermal growth factor receptor (EGFR) mutations (u-EGFRm) are
a heterogeneous group of molecular alterations and have also been reported as …
a heterogeneous group of molecular alterations and have also been reported as …
Survival of chemo-naïve patients with EGFR mutation-positive advanced non-small cell lung cancer after treatment with afatinib and bevacizumab: updates from the …
T Ninomiya, N Nogami, T Kozuki… - Japanese journal of …, 2021 - academic.oup.com
Background In a phase I study, afatinib (30 mg/body daily) plus bevacizumab (15 mg/kg
every 3 weeks) was well tolerated and showed favourable outcomes in patients with …
every 3 weeks) was well tolerated and showed favourable outcomes in patients with …
Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are a standard of
care in the first-line treatment of patients with EGFR mutation-positive metastatic non-small …
care in the first-line treatment of patients with EGFR mutation-positive metastatic non-small …
Real-world Afatinib Outcomes in Advanced Non–small Cell Lung Cancer Harboring EGFR Mutations
CH Chen, JWC Chang, CF Chang… - Anticancer …, 2022 - ar.iiarjournals.org
Background/Aim: Afatinib is a standard treatment for patients with advanced non–small cell
lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations …
lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations …
Afatinib treatment alone or with bevacizumab in a real-world cohort of non-small cell lung cancer patients with epidermal growth factor receptor mutation
CHS Kuo, TH Chiu, PH Tung, CH Huang, JS Ju… - Cancers, 2022 - mdpi.com
Simple Summary Previous studies of first-generation EGFR-TKI erlotinib and bevacizumab
combination have demonstrated superior treatment efficacy compared to erlotinib …
combination have demonstrated superior treatment efficacy compared to erlotinib …